Larimar Therapeutics (LRMR) Share-based Compensation (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Share-based Compensation for 14 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 28.81% year-over-year to $11.1 million; the trailing twelve-month figure through Jun 2026 stood at $11.1 million (up 28.81% YoY), and the FY2025 full-year result was $10.2 million, down 4.67% from the prior year.
• Share-based Compensation climbed to $11.1 million in Q2 2026 per LRMR's latest filing, from $1.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.1 million in Q2 2026 and bottomed at $1.6 million in Q4 2025.
• Historically, Share-based Compensation has averaged $5.0 million across 5 years, with a median of $4.5 million in 2023.
• The widest YoY moves for Share-based Compensation: up 46.05% in 2025, down 35.39% in 2025.
• Over 5 years, Share-based Compensation stood at $1.6 million in 2022, then grew by 16.74% to $1.9 million in 2023, then grew by 25.65% to $2.4 million in 2024, then slumped by 35.39% to $1.6 million in 2025, then surged by 610.1% to $11.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $11.1 million, $1.6 million, and $8.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.